focal cortical dysplasia type 2

临床试验

计划入组 23 人

已完成

jRCTs041190059

Study about safety of sirolimus: Shizuoka 2019-1 ((Sirolimus Shizuoka 2019-1))

计划入组 5 人

已完成

jRCTs011180016

Research of sirolimus administration for FCD II type (Research of sirolimus administration for FCD II type)

计划入组 2 人

药物

查看全部 7758 →

MIF antagonists (Cortical)

focal adhesion kinase

Biotech

Approved

Poliovirus type 2 antigen (formaldehyde inactivated)(Ipol, Kinrix, Pediarix, Pentacel, Quadracel, Vaxelis)

相关疾病：Poliomyelitis caused by Poliovirus, Poliomyelitis caused by poliovirus type 2

机构

查看全部 1440 →

UpJohn US 2 LLC

United States

MEREO BIOPHARMA 2 LIMITED

United Kingdom

RIVER 2 RENAL CORP.

United States

资讯

查看全部 16780 →

昨天

Sovargen Doses First Patient in Phase 1b/2a Trial of Kazia's Paxalisib for FCD T2 and TSC Epilepsy

2个月前

Single-Nucleus Transcriptomics-Based Drug Screening Platform Identifies Candidate Compounds for Focal Cortical Dysplasia

16天前

临床试验

Research of sirolimus administration for FCD II type (FCDS-02)

Study about safety of sirolimus: Shizuoka 2019-1 ((Sirolimus Shizuoka 2019-1))

Research of sirolimus administration for FCD II type (Research of sirolimus administration for FCD II type)

药物

MIF antagonists (Cortical)

focal adhesion kinase

Poliovirus type 2 antigen (formaldehyde inactivated)(Ipol, Kinrix, Pediarix, Pentacel, Quadracel, Vaxelis)

机构

UpJohn US 2 LLC

MEREO BIOPHARMA 2 LIMITED

RIVER 2 RENAL CORP.

资讯

Sovargen Doses First Patient in Phase 1b/2a Trial of Kazia's Paxalisib for FCD T2 and TSC Epilepsy

Single-Nucleus Transcriptomics-Based Drug Screening Platform Identifies Candidate Compounds for Focal Cortical Dysplasia

PannTheraPi Receives ANSM Approval to Advance First-in-Class Panx1-Targeting Therapy PTI5803 into Phase 2a in Focal Cortical Dysplasia